Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Jun 15;57(3):355–365. doi: 10.1007/s40262-017-0562-0

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2017

Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

PMC Copyright notice

Fig. 3 — Effect of anti-drug antibody titers on olaratumab pharmacokinetics. a Sample time course of olaratumab serum concentration (grey) overlaid with time course of anti-drug antibody titer (red) in patients tested positive for treatment-emergent anti-drug antibody. b Post hoc clearance estimates of patients negative for TE-ADAs versus those positive for TE-ADAs. ADA anti-drug antibody, CL clearance, NSCLC nonsmall cell lung cancer, PK pharmacokinetic, STS soft tissue sarcoma, TE-ADAs treatment-emergent anti-drug antibodies